刚果民主共和国金沙萨两次涉及新亚分支Ia的猴痘疫情流行病学与系统发育基因组学特征:一项回顾性观察研究
该回顾性观察研究分析了2023年1月1日至2024年10月31日金沙萨报告的1479例疑似猴痘病例,其中1314例经PCR检测,440例(34%)确诊。疫情呈两个时期:2023年8月18日至2024年6月30日(时期1)确诊24例(11%),均为亚分支Ia;2024年7月1日至10月31日(时期2)确诊416例(38%),出现亚分支Ib。基因组分析显示亚分支Ia的APOBEC3驱动突变增加,支持人际传播增强。
要点
- 金沙萨2023-24年猴痘疫情分两期:时期1(2023年8月18日至2024年6月30日)确诊24例(11%),均为亚分支Ia;时期2(2024年7月1日至10月31日)确诊416例(38%),出现亚分支Ib。
- 时期1发现三个小而自限的传播链(2023年8月至9月);亚分支Ia组II有五个独立自限簇,时期2出现两个较大簇(亚分支Ia组II和亚分支Ib)。
- 亚分支Ia簇疫情中47个突变有32个(68%)、亚分支Ib疫情中39个突变有28个(72%)与APOBEC3驱动改变一致,支持向人际传播转变。
核心结论
- 自2023年记录到亚分支Ia多次自限性引入后出现持续人际传播,自2024年7月起与亚分支Ib在金沙萨共同循环。
- 新亚分支Ia谱系中APOBEC3驱动改变增加支持向人际传播转变。
- 这些发现揭示猴痘传播动力学的重要变化,并提示任何猴痘病毒亚分支在有利传播条件下均有可能引起持续人间疫情。
研究设计与样本
- 回顾性观察研究,纳入2023年1月1日至2024年10月31日金沙萨报告的疑似和实验室确诊猴痘病例。
- 共报告1479例疑似病例,其中1314例采集样本并在国家生物医学研究所(INRB)经实时PCR检测。
- 对样本进行全基因组测序用于系统发育分析和APOBEC3型突变评估;测序和PCR后未归入亚分支Ia或Ib的样本标记为未知亚分支。
主要发现
- 1314例疑似病例中440例(34%)经PCR确诊猴痘,首例确诊病例于2023年8月18日检出。
- 440例确诊病例中男性262例(60%)、女性172例(39%)、性别未知6例(1%),中位年龄26岁(IQR 19-34)。
- 时期1(2023年8月18日至2024年6月30日)调查218例疑似病例,24例(11%)经PCR确诊,均为亚分支Ia。
- 时期2(2024年7月1日至10月31日)报告1096例疑似病例,416例(38%)经PCR确诊;2024年7月1日报告金沙萨首例确诊亚分支Ib病例。
- 亚分支Ia有临床数据者61例(95例中64%),最常见症状为发热49例(80%)和皮疹48例(79%);55例有皮损部位数据者中生殖器或肛直肠部位35例(64%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Clade I monkeypox virus is endemic in DR Congo. We aim to describe the epidemiological trends of the cocirculating subclades Ia and Ib mpox outbreaks in Kinshasa, DR Congo. METHODS: This retrospective observational study included suspected and laboratory-confirmed mpox cases reported between Jan 1, 2023, and Oct 31, 2024, in Kinshasa. Skin lesion swabs or blood samples were collected as part of a routine countrywide mpox surveillance programme. To confirm the diagnosis of mpox, all samples were tested at the Institut National de Recherche Biomédicale (INRB) using real-time PCR. Whole-genome sequencing was conducted for phylogenomic analysis and assessment of APOBEC3 type mutations. Samples that remained unassigned to subclade Ia or Ib after whole-genome sequencing and real-time PCR were labelled as an unknown subclade. FINDINGS: As part of routine disease surveillance, 1479 suspected mpox cases were reported in Kinshasa. Samples were collected from 1314 suspected mpox cases and tested by PCR at the INRB. 440 (34%) of 1314 suspected cases had PCR confirmed mpox, with the first confirmed mpox case detected on Aug 18, 2023. 262 (60%) of 440 cases were male, 172 (39%) were female, and six (1%) were unknown, and the median age was 26 years (IQR 19-34). The epidemiological curve suggests two distinct periods during the 2023-24 outbreaks in Kinshasa. Between Aug 18, 2023, and June 30, 2024 (period 1), 218 suspected mpox cases underwent investigation and 24 (11%) were PCR confirmed as mpox; all cases were identified as subclade Ia. After a decline in suspected and confirmed cases in early 2024, the first confirmed subclade Ib mpox case in Kinshasa was reported on July 1, 2024. Between July 1 and Oct 31, 2024 (period 2), 1096 suspected mpox cases were reported and 416 (38%) were PCR confirmed as mpox. In-depth epidemiological case investigations during period 1 identified three small, self-limiting transmission chains between August and September, 2023. Case investigation data were available for 127 cases with PCR confirmed mpox, including clinical symptom data available for 61 (64%) of 95 with subclade Ia. The most commonly reported symptoms were fever (49 [80%] of 61) and skin rash (48 [79%]). The most common lesion locations were genital or anorectal (35 [64%] of 55 cases with available data). Case investigation data were available for 32 cases with subclade Ib mpox, including clinical symptom data available for 21 (66%) with subclade Ib. The most commonly reported symptoms were skin rash (18 [86%] of 21) and fever (12 [57%]). Genital or anorectal involvement was reported in 13 (68%) of 19 cases with available lesion location data. Genomic analysis shows five separate self-limiting clusters of subclade Ia (group II sampled from August, 2023, to August, 2024) and two larger clusters (occurring from July, 2024, to October, 2024, in period 2) belonging to subclade Ia (group II) and subclade Ib. 32 (68%) of 47 mutations for subclade Ia cluster outbreak and 28 (72%) of 39 mutations for subclade Ib outbreak were consistent with APOBEC3 driven changes. INTERPRETATION: Sustained human-to-human transmission occurred after repeated self-limiting introductions of subclade Ia documented since 2023, which has cocirculated with subclade Ib in Kinshasa from July, 2024. Increased APOBEC3 driven changes in the new subclade Ia lineage support a shift towards human-to-human transmission. These findings reveal important changes in mpox transmission dynamics and suggests that any monkeypox virus subclade has the potential to cause sustained human outbreaks when favourable transmission conditions are met. FUNDING: Belgian Directorate-General for Development Cooperation and Humanitarian Aid; the Research Foundation Flanders; Institute of Tropical Medicine Structurele Onderzoeksfinanciering (Flemish Government; Science, Technology, and Innovation); Global Health European and Developing Countries Clinical Trials Partnership 3 Joint Undertaking; the US Department of Defense Threat Reduction Agency; the US Department for Agriculture Research Service; Canadian Institutes of Health Research; International Development Research Centre; US National Institute of Allergy and Infectious Diseases, National Institutes of Health; and Wellcome Trust.
引用
- Wawina-Bokalanga T, Merritt S, Kinganda-Lusamaki E, et al. Epidemiology and phylogenomic characterisation of two distinct mpox outbreaks in Kinshasa, DR Congo, involving a new subclade Ia lineage: a retrospective, observational study. Lancet. 2025. PMID: 40617661. doi:10.1016/S0140-6736(25)00294-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。